• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

较高搅拌速率对速释药品释放模式的影响。

Influence of higher rates of agitation on release patterns of immediate-release drug products.

作者信息

Shah V P, Gurbarg M, Noory A, Dighe S, Skelly J P

机构信息

Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857.

出版信息

J Pharm Sci. 1992 Jun;81(6):500-3. doi: 10.1002/jps.2600810604.

DOI:10.1002/jps.2600810604
PMID:1522485
Abstract

The dissolution procedure serves as a quality control test to assure batch-to-batch uniformity and bioequivalence of a product once the bioavailability of the product has been established. It can also be used to detect manufacturing and/or process variations that could reduce product bioavailability. Dissolution testing must be conducted at an appropriate agitation rate. Tests conducted at high agitation rates may lose the ability to differentiate between good and bad products. Although the effect of high agitation rates has been known for some time, several immediate-release drug products still have United States Pharmacopeia (USP) monograph dissolution procedures that require very high agitation rates. A systematic survey was conducted on marketed tablets of chloroquine phosphate, griseofulvin, hydroxychloroquine sulfate, isocarboxazide, primaquine phosphate, and sulfadiazine. Each of these products has a USP monograph requiring a dissolution test at a paddle speed of 100 rpm. To study the influence of agitation rate on the dissolution rate of these products, dissolution studies were conducted at paddle speeds of 50, 75, and 100 rpm with the USP apparatus 2 (paddle method). The dissolution rate increased with an increase in the agitation rate from 50 to 75 rpm. However, no significant increase in the dissolution rate was noted with an increase in the agitation rate from 75 to 100 rpm. The data support the position that the higher agitation rate of 100 rpm is not necessary for a quality control procedure or a compendial standard for the products tested.

摘要

一旦确定了产品的生物利用度,溶出度测定程序可作为一种质量控制测试,以确保产品批次间的一致性和生物等效性。它还可用于检测可能降低产品生物利用度的生产和/或工艺变化。溶出度测试必须以适当的搅拌速率进行。在高搅拌速率下进行的测试可能会失去区分优质产品和劣质产品的能力。尽管高搅拌速率的影响已经为人所知一段时间了,但仍有几种速释药品的美国药典(USP)专论溶出度测定程序要求非常高的搅拌速率。对市售的磷酸氯喹、灰黄霉素、硫酸羟氯喹、异卡波肼、磷酸伯氨喹和磺胺嘧啶片剂进行了系统调查。这些产品中的每一种都有USP专论,要求在桨板转速为100转/分钟的条件下进行溶出度测试。为了研究搅拌速率对这些产品溶出速率的影响,使用USP装置2(桨板法)在桨板转速为50、75和100转/分钟的条件下进行了溶出度研究。溶出速率随着搅拌速率从50转/分钟增加到75转/分钟而增加。然而,随着搅拌速率从75转/分钟增加到100转/分钟,未观察到溶出速率有显著增加。数据支持这样的观点,即对于所测试的产品,100转/分钟的较高搅拌速率对于质量控制程序或药典标准来说并非必要。

相似文献

1
Influence of higher rates of agitation on release patterns of immediate-release drug products.较高搅拌速率对速释药品释放模式的影响。
J Pharm Sci. 1992 Jun;81(6):500-3. doi: 10.1002/jps.2600810604.
2
Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.基于右酮洛芬片生物药剂学分类豁免研究的BCS生物豁免完全溶解的搅拌速率和时间
Mol Pharm. 2015 Sep 8;12(9):3194-201. doi: 10.1021/acs.molpharmaceut.5b00131. Epub 2015 Aug 10.
3
Evaluation of USP apparatus 3 for dissolution testing of immediate-release products.美国药典装置3用于速释产品溶出度测试的评估。
AAPS PharmSci. 2002;4(1):E1. doi: 10.1208/ps040101.
4
Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.理解美国药典装置I和II对具有不同释放机制的片剂溶出动力学影响的机制方法。
AAPS PharmSciTech. 2017 Feb;18(2):462-472. doi: 10.1208/s12249-016-0535-x. Epub 2016 Apr 22.
5
Temperature, pH and agitation rate as dissolution test discriminators of zofenopril calcium tablets.温度、pH值和搅拌速率作为佐芬普利钙片溶出度试验的判别因素
J Pharm Biomed Anal. 1994 Feb;12(2):173-7. doi: 10.1016/0731-7085(94)90027-2.
6
New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.USP 仪器 3 在溶出度测试中的新应用方法:三种抗高血压即释片的案例研究。
AAPS PharmSciTech. 2018 Oct;19(7):2866-2874. doi: 10.1208/s12249-018-1086-0. Epub 2018 Jun 22.
7
Effects of Apex Size on Dissolution Profiles in the USP II Paddle Apparatus.顶空大小对 USP II 桨法装置中溶出曲线的影响。
AAPS PharmSciTech. 2023 Dec 29;25(1):9. doi: 10.1208/s12249-023-02722-5.
8
Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.使用生物等效的盐酸多西环素药品对比世界卫生组织(WHO)和美国食品药品监督管理局(US FDA)的生物豁免溶出度测试条件。
J Pharm Pharmacol. 2009 Mar;61(3):331-7. doi: 10.1211/jpp/61.03.0007.
9
A better dissolution method for ranitidine tablets USP.美国药典雷尼替丁片的一种更佳溶出方法。
Pharm Dev Technol. 2001;6(1):11-7. doi: 10.1081/pdt-100000008.
10
Applications of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products.一种用于改进药品药物释放(溶出度)表征的新装置(轴)的应用。
Eur J Pharm Sci. 2003 Jul;19(4):291-7. doi: 10.1016/s0928-0987(03)00120-9.

引用本文的文献

1
Kinetic and Methodological Insights into Hydrophilic Drug Release from Mesoporous Silica Nanocarriers.介孔二氧化硅纳米载体中亲水性药物释放的动力学及方法学见解
Pharmaceutics. 2025 May 25;17(6):694. doi: 10.3390/pharmaceutics17060694.
2
release studies of furosemide reference tablets: influence of agitation rate, USP apparatus, and dissolution media.呋塞米参比片的释放度研究:搅拌速率、美国药典装置及溶出介质的影响
ADMET DMPK. 2020 Jun 29;8(4):411-423. doi: 10.5599/admet.801. eCollection 2020.
3
Hydrogels as Drug Delivery Systems: A Review of Current Characterization and Evaluation Techniques.
水凝胶作为药物递送系统:当前表征与评估技术综述
Pharmaceutics. 2020 Dec 7;12(12):1188. doi: 10.3390/pharmaceutics12121188.
4
Logic of Selecting Suitable Dissolution Parameters in New Drug Formulations Based on A BCS Approach.基于生物药剂学分类系统(BCS)方法选择新药制剂合适溶出参数的逻辑
Iran J Pharm Res. 2020 Winter;19(1):465-486. doi: 10.22037/ijpr.2020.1100993.
5
Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules.雷贝拉唑钠缓释胶囊在酸性介质中溶出度测试的开发与验证
Drug Dev Ind Pharm. 2016 Oct;42(10):1669-77. doi: 10.3109/03639045.2016.1161644. Epub 2016 Apr 11.
6
Development of a dialysis in vitro release method for biodegradable microspheres.用于可生物降解微球的透析体外释放方法的开发。
AAPS PharmSciTech. 2005 Oct 6;6(2):E323-8. doi: 10.1208/pt060242.
7
Perspectives of in vitro dissolution tests in establishing in vivo/in vitro correlations.
Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):7-18. doi: 10.1007/BF03220004.